For biotech and medtech companies, a high patient retention rate in clinical trials is not merely a desirable outcome; it's a critical determinant of trial success, data integrity, and ultimately, reg...
For biotech and medtech companies, a high patient retention rate in clinical trials is not merely a desirable outcome; it's a critical determinant of trial success, data integrity, and ultimately, regulatory approval. While global benchmarks often hover around 70-80%, striving for and achieving an exceptional 95% patient retention rate can significantly reduce costs, accelerate timelines, and provide more robust data. In the diverse and rapidly expanding markets of Latin America, accomplishing such a high retention rate requires a nuanced understanding of local cultures, healthcare systems, and patient needs. This is where bioaccess®, with its deep regional expertise, transforms ambitious targets into tangible results. Latin America offers a compelling landscape for clinical research: large, treatment-naïve patient populations, highly motivated investigators, and competitive operational costs. However, capitalizing on these advantages while maintaining superior patient engagement dema…